Avaliação da fluorescência de duas resinas compostas após imersão em soluções pigmentantes

Dissertação para obtenção do grau de Mestre no Instituto Superior de Ciências da Saúde Egas MonizObjectivo: O objectivo deste estudo consiste na avaliação in vitro da fluorescência de duas resinas compostas, frequentemente usadas na prática clínica, antes e após a imersão em soluções pigmentantes. Materiais e Métodos: 10 discos de resina composta (10mm de diâmetro e 2mm de espessura) foram confeccionados a partir de duas resinas compostas fotopolimerizáveis (uma nanoparticulada e uma híbrida) através de um molde metálico standardizado. Todos os discos sofreram um corte de 2 mm no seu diâmetro. Seguidamente, realizou-se o polimento. Oito discos foram imersos em saliva artificial durante 24 horas e posteriormente durante 72 horas nas respectivas soluções pigmentantes: água destilada, vinho tinto, café e black vodka. Dois discos não foram imersos. Os gráficos de fluorescência para cada disco foram obtidos a partir de um espectrofluorímetro e os dados foram tratados através de uma análise qualitativa e interpretativa. Resultados: A exposição dos discos de resina composta aos fluídos pigmentantes diminuiu, de forma significativa, a intensidade de fluorescência por eles inicialmente emitida. A alteração de fluorescência mais acentuada verificou-se no FiltekTM Supreme XTE A3B sob a ação do vinho tinto e, a menos acentuada, no FiltekTM Z250 A3 sob a ação da água destilada. A solução que demonstrou causar mais alterações foi o vinho tinto e a que provocou menos alterações foi a água destilada. Conclusões: As duas resinas compostas sofreram diferentes alterações de fluorescência, perante os diferentes agentes pigmentantes, sendo esta alteração dependente da natureza da matriz orgânica, partículas de carga e do tipo de agente pigmentante

Avaliação da fluorescência de 2 resinas compostas após imersão em soluções pigmentantes

Poster apresentado no XXXV Congresso Anual da Sociedade Portuguesa de Estomatologia e Medicina Dentária (SPEMD), 9-10 Outubro 2015, Centro de Congressos do Lagoas Park, Oeiras, Lisboa.Under a Creative Commons license - http://creativecommons.org/licenses/by-nc-nd/4.0

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Background: In a phase 1b study, intravenous daratumumab plus pomalidomide and dexamethasone induced a very good partial response or better rate of 42% and was well tolerated in patients with heavily pretreated multiple myeloma. We aimed to evaluate whether daratumumab plus pomalidomide and dexamethasone would improve progression-free survival versus pomalidomide and dexamethasone alone in patients with previously treated multiple myeloma. Methods: In this ongoing, open-label, randomised, phase 3 trial (APOLLO) done at 48 academic centres and hospitals across 12 European countries, eligible patients were aged 18 years or older, had relapsed or refractory multiple myeloma with measurable disease, had an Eastern Cooperative Oncology Group performance status of 0–2, had at least one previous line of therapy, including lenalidomide and a proteasome inhibitor, had a partial response or better to one or more previous lines of antimyeloma therapy, and were refractory to lenalidomide if only one previous line of therapy was received. Patients were randomly assigned (1:1) by an interactive web-response system in a random block size of two or four to receive pomalidomide and dexamethasone alone or daratumumab plus pomalidomide and dexamethasone. Randomisation was stratified by number of previous lines of therapy and International Staging System disease stage. All patients received oral pomalidomide (4 mg, once daily on days 1–21) and oral dexamethasone (40 mg once daily on days 1, 8, 15, and 22; 20 mg for those aged 75 years or older) at each 28-day cycle. The daratumumab plus pomalidomide and dexamethasone group received daratumumab (1800 mg subcutaneously or 16 mg/kg intravenously) weekly during cycles 1 and 2, every 2 weeks during cycles 3–6, and every 4 weeks thereafter until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival in the intention-to-treat population. Safety was analysed in all patients who received at least one dose of study medication. This trial is registered with ClinicalTrials.gov, NCT03180736. Findings: Between June 22, 2017, and June 13, 2019, 304 patients (median age 67 years [IQR 60–72]; 161 [53%] men and 143 [47%] women) were randomly assigned to the daratumumab plus pomalidomide and dexamethasone group (n=151) or the pomalidomide and dexamethasone group (n=153). At a median follow-up of 16·9 months (IQR 14·4–20·6), the daratumumab plus pomalidomide and dexamethasone group showed improved progression-free survival compared with the pomalidomide and dexamethasone group (median 12·4 months [95% CI 8·3–19·3] vs 6·9 months [5·5–9·3]; hazard ratio 0·63 [95% CI 0·47–0·85], two-sided p=0·0018). The most common grade 3 or 4 adverse events were neutropenia (101 [68%] of 149 patients in the daratumumab plus pomalidomide and dexamethasone group vs 76 [51%] of 150 patients in the pomalidomide and dexamethasone group), anaemia (25 [17%] vs 32 [21%]), and thrombocytopenia (26 [17%] vs 27 [18%]). Serious adverse events occurred in 75 (50%) of 149 patients in the daratumumab plus pomalidomide and dexamethasone group versus 59 (39%) of 150 patients in the pomalidomide and dexamethasone group; pneumonia (23 [15%] vs 12 [8%] patients) and lower respiratory tract infection (18 [12%] vs 14 [9%]) were most common. Treatment-emergent deaths were reported in 11 (7%) patients in the daratumumab plus pomalidomide and dexamethasone group versus 11 (7%) patients in the pomalidomide and dexamethasone group. Interpretation: Among patients with relapsed or refractory multiple myeloma, daratumumab plus pomalidomide and dexamethasone reduced the risk of disease progression or death versus pomalidomide and dexamethasone alone and could be considered a new treatment option in this setting. Funding: European Myeloma Network and Janssen Research and Development.European Myeloma Network and Janssen Research and Development

Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial

In the phase 3 APOLLO trial, daratumumab in combination with pomalidomide and dexamethasone (D-Pd) significantly reduced the rate of disease progression or death by 37% relative to Pd alone in patients with relapsed/refractory multiple myeloma (RRMM) who had received ≥1 prior line of therapy including lenalidomide and a proteasome inhibitor. Here, we present patient-reported outcomes (PROs) from APOLLO. Median treatment duration was 11.5 months with D-Pd and 6.6 months with Pd. PRO compliance rates were high and similar in both groups. No changes from baseline were observed for EORTC QLQ-C30 global health status scores in either group, while physical and emotional functioning, disease symptoms, and adverse effects of treatment remained at baseline levels with D-Pd but worsened with Pd. Reductions (p < 0.05) in pain and fatigue were seen at several time points with D-Pd versus Pd. Overall, these results suggest patients' health-related quality of life remained stable when daratumumab was added to Pd, with several results favoring D-Pd versus Pd. These findings complement the significant clinical improvements observed with D-Pd and support its use in patients with RRMM.The APOLLO study was sponsored by the European Myeloma Network (EMN) in collaboration with Janssen Research & Development, LLC. Medical writing and editorial support were provided by Justine Lempart, PhD, and Linda V. Wychowski, PhD, of Eloquent Scientific Solutions and were funded by Janssen Global Services, LL

Práticas artísticas no ensino básico e secundário

O terceiro número da Revista Matéria-Prima afirma-se como mais uma plataforma de disseminação e de registo na área da educação e ensino artísticos. Ao propor-se o desafio da Matéria-Prima está a lançar-se um repto de intervenção e partilha a três tipos de intervenientes na educação pela arte: — Os professores, profissionais experimentados; — Os que se iniciam na profissão, através da frequência de mestrados e estágios formativos; — Os investigadores e professores universitários desta área. Esta chamada coloca em cima da mesa a partilha das experiências didácticas em sala de aula, a pesquisa sobre práticas profissionais. Experiências, algumas bem-sucedidas, outras menos, porventura, todas com um mérito substancial, que é a vontade de estabelecer comunidade entre os interessados pela educação artística. Este conjunto de textos poderá ajudar a cartografar práticas que se observam bastante distintas, entre as realidades dos países representados, Portugal, Espanha, Brasil, Argentina. Observa-se também que a prática dos educadores está longe de ser homogénea. É surpreendente determinar as diferenças entre contextos e regiões. Se umas são mais metódicas, e por isso consistentes, outras abrem-se à descoberta. Em todas um ponto de encontro: a revista Matéria-Prima, que assim assume cada vez mais o seu nome como um desígnio de intervenção.info:eu-repo/semantics/publishedVersio

Chemistry REACTION OF ARENEDIAZONIUM CHLORIDES AND SULFUR(IV) OXIDE WITH (2E,6E)-2,6-DIBENZYLIDENECYCLOHEXANONE AND (2E,2&apos;E)-3,3&apos;- BENZENE-1,4-DIYL-BIS(1-PHENYLPROP-2-EN-1-ONE)

Abstract. It has been established that cuprous catalytic reaction of (2E,6E)-2,6-dibenzylidenecyclohexanone or (2E,2&apos;E)-3,3&apos; -benzene -1,4-diyl-bis(1-phenylprop-2-en-1-one) with arenediazonium chloride and sulfur(IV) oxide leads to the formation of arylsulfonylation product by only one double bond. Substituted 2-benzyliden-6-[(arylsulfonyl)(phenyl)methyl]cyclohexanones and 3[4-(1-arylsulfonyl-3-oxo-3-phenylpropyl)phenyl]-1-phenylprop-2-en-1-ones) have been obtained